TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03925662

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folfox with avastin
Description: Folfox with avastin only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mebendazole
Description: Folfox with avastin with mebendazole
Study: NCT03645005

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My Guide (psychoeducation & self-management program)
Description: My Guide is a Smartphone application incorporating elements informed by the extant literature, designed to improve quality of life and symptom burden among Hispanic breast cancer survivors. My Guide components are designed to improve breast cancer knowledge, cancer-relevant self-efficacy, stress and symptom management skills, Both intervention and active comparator conditions are administered to participants for 8 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: My Health (health education program)
Description: My Health is a health promotion Smartphone application with health education content on nutrition, and general advice on lifestyle choices and prevention. The My Health control content was based on similar content tested in other psychosocial interventions with cancer survivors. Both intervention and active comparator conditions are administered to participants for 8 weeks.
Study: NCT02845713

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin, Diethylcarbamazine Albendazole (IDA)
Description: To evaluate the safety and tolerability of triple drug therapy (a single dose of ALB, IVM and DEC)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin, Diethylcarbamazine Albendazole (IDA)
Description: To evaluate the safety and tolerability of triple drug therapy (a single dose of ALB, IVM and DEC)
Study: NCT03503487

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D informed consent
Description: Patients were given an informed consent with the aid of a 3D immersive surgical planner (either a Surgical Theater or Vesalius)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D informed consent
Description: Patients were given an informed consent with the aid of a 3D immersive surgical planner (either a Surgical Theater or Vesalius)
Study: NCT03187041

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensation and Skin Surface Pressures Under Blood-Draw Tourniquets
Description: Phase 1: Skin surface pressures will be recorded by an investigator during each of the 10 applications of the tourniquet. All 10 tourniquet skin pressure measurements will take place in the Blood Draw clinic at the UCSD Medical Center in Hillcrest on the same day for a subject.~Phase 2: The same 20 subjects will be subjected to a prolonged blood-draw tourniquet application for a duration of 70 minutes. The purpose of phase 2 is to determine whether there is an effect on sensation from prolonged blood tourniquet use. External skin pressures will not exceed 60mmHg. During this prolonged tourniquet application the investigators will monitor changes in hand sensation at 10-minute intervals using Semmes-Weinstein monofilaments on three peripheral nerves of the hand (median, radian, and ulnar).
Study: NCT02917798

Intervention type: BEHAVIORAL
Intervention: Assessments
Study: NCT04392479

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept-FOLFIRI
Description: Aflibercept-FOLFIRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept-mFOLFIRI3
Description: Aflibercept-mFOLFIRI3
Study: NCT01763034

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: limb ischemic preconditioning
Description: use a simple blood pressure cuff inflate for 5 minutes and deflate for 5 minutes alternately in each arms total = 3 cycle in each arm
Study: NCT02991703

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pOpmètre®
Description: the pOpmètre® uses saturation sensors,

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sphygmocor
Description: the Sphygmocor uses applanation tonometry
Study: NCT03413540

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Jump
Description: Drop jump from step

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Jump
Description: Drop jump from step

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Jump
Description: Drop jump from step

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Jump
Description: Drop jump from step

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Jump
Description: Drop jump from step

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Jump
Description: Drop jump from step

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Jump
Description: Drop jump from step

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Jump
Description: Drop jump from step

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Jump
Description: Drop jump from step
Study: NCT02455284

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: In vivo MRI with B0 cartography, FLAIR, 3D T1 anatomic images, DWI, and Tractography from DWI images
Study: NCT04189341

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block (Group E)
Description: Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modified-thoracolumbar interfascial plane block
Description: Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
Study: NCT01376050

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Erchonia ML Scanner (MLS)
Description: Erchonia MLS comprises three 17.5 mW 635 nm diodes. The center diode is fixed at 6 inches above the venous stasis ulcer center and the other 2 diodes rotate about this center fixed diode for 20 minutes. Total dosage delivered to the skin is 2.95 J/cm squared.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Laser
Description: Placebo Laser has no therapeutic output emitted.
Study: NCT03431480

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Human Placental Cord Blood Mononuclear Cells
Description: Autologous human placental cord blood mononuclear cells are infused into the coronary artery during the Norwood heart operation
Study: NCT02935777

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pomegranate Extract
Description: The first computer cognitive testing session lasting approximately 45 minutes is undertaken by participants. After completion, intervention capsules are administered. After a 60 minute absorption period, the cognitive testing session is re-administered.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: One computer cognitive testing session lasting approximately 45 minutes is undertaken by participants. After completion, placebo capsules are administered. After a 60 minute absorption period, the cognitive testing session is re-administered.
Study: NCT02666170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid
Study: NCT04511949

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: COVID-19 IgG / IgM rapid test (whole blood, serum, plasma)
Description: * The rapid test is performed using a drop of blood obtained at the fingertip (10 microliters) using a lancet.~* The dropper pipette, held vertically, collects the drop of whole blood up to the sample line~* Place 1 drop of whole blood (10 μL in the sample well (S) of the cassette.~* Immediately add 2 drops (80μL) of buffer to the well (B) of the cassette.~* Avoid air bubbles; if there is an air bubble, add a 3rd drop of buffer.~The reading is taken after 10 minutes at most by the healthcare professional under medical supervision.~In case of sepositivity of the rapid test, it may be offered to index cases and adult contacts, a blood sample of 5 ml of blood for a serothèque allowing a characterization of the antibodies and in particular of the neutralizing antibodies.
Study: NCT00005005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTH

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTH

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PTH
Study: NCT00053352

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bleomycin sulfate
Description: Given IV
Study: NCT00005005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate
Study: NCT02122081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation
Description: Undergo allogeneic peripheral blood progenitor cell or bone marrow transplant on day 0

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Undergo allogeneic peripheral blood progenitor cell or bone marrow transplant
Study: NCT00005005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate
Study: NCT03013764

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: normal protein diet
Description: subjects will undergo 10 days of low physical activity while consuming a normal protein diet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: high protein intake
Description: subjects will undergo 10 days of low physical activity while consuming a high protein diet
Study: NCT04291456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline 100mg
Description: Single-arm trial of minocycline 100 mg twice daily
Study: NCT02887222

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 0.0625% Bupivacaine plus fentanyl 2mcg/ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 0.0625% Bupivacaine plus fentanyl 2mcg/ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 0.0625% Bupivacaine plus fentanyl 2mcg/ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 0.0625% Bupivacaine plus fentanyl 2mcg/ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 0.0625% Bupivacaine plus fentanyl 2mcg/ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 0.0625% Bupivacaine plus fentanyl 2mcg/ml
Study: NCT00053352

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03191214

Intervention type: DEVICE
Intervention: Intraoperative Forced Air Warming
Description: As part of their standard care, patients undergoing surgery \>30 min in duration will receive forced air warming in the form of a Bair Hugger. This is a blanket covering their upper torso and arms into which warm air is blown.
Study: NCT04181437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP-1203-R1
Description: 1 tablet, Single oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP-1203-R2
Description: 1 tablet, Single oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP-1203-R1 and NVP-1203-R2
Description: NVP-1203-R1,1 tablet and NVP-1203-R2, 1 tablet, co-administration, single oral dosing
Study: NCT03024528

Intervention type: BEHAVIORAL
Intervention: CPOT assessment
Description: Polish version of Critical care pain observation tool validation.

Intervention type: BEHAVIORAL
Intervention: CPOT assessment
Description: Polish version of Critical care pain observation tool validation.
Study: NCT04385875

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine + extension of the ATI period
Description: During the AELIX-002 trial participants received the following: DNA.HTI at weeks 0, 4, and 8 and MVA.HTI at weeks 12 and 20 (DDDMM) followed by ChAdOx1.HTI at weeks 0 and 12 and MVA.HTI at week 24 (CCM), starting at least 24 weeks after MVA.HTI week 20. After that, on ATI_extension trial, ATI will be extended for 48 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + extension of the ATI period
Description: During the AELIX-002 trial participants received the following: Normal saline solution at weeks 0, 4, 8, 12, and 20 (PPPPP) followed by normal saline solution at weeks 0, 12 and 24 (PPP), starting at least 24 weeks after week 20 administration. After that, on ATI_extension trial, ATI will be extended for 48 weeks.
Study: NCT01428687

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Duration
Description: Subjects are taught sleep hygiene strategies to increase their sleep; they record their sleep in a diary and wear an actigraph and call in their sleep to the office each day.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Duration
Description: Subjects are taught sleep hygiene strategies to increase their sleep; they record their sleep in a diary and wear an actigraph and call in their sleep to the office each day.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No change in sleep
Description: This group is taught to maintain their current sleep habits.
Study: NCT00932451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02341066
Description: PF-02341066, 250 mg BID, will be administered orally on a continuous schedule
Study: NCT01712893

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoladex
Description: Eligible patients were randomly divided into 2 groups, the intervention group should use Zoladex 3.6mg once a month up to 2-3 years combined with chemotherapy,and the control group should use chemotherapy alone followed by Zoladex

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoladex
Description: Eligible patients were randomly divided into 2 groups, the intervention group should use Zoladex 3.6mg once a month up to 2-3 years combined with chemotherapy,and the control group should use chemotherapy alone followed by Zoladex
Study: NCT03652948

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meru Health Ascend Program
Description: Cognitive-behavioral skills, mindfulness
Study: NCT04007107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide (administered by DV3396 pen)
Description: Subjects will receive 1 single dose of semaglutide 0.25 mg on 1 day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide (administered by DV3396 pen)
Description: Subjects will receive 1 single dose of semaglutide 0.25 mg on 1 day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide (administered by PDS290 pen)
Description: Subjects will receive 1 single dose of semaglutide 0.25 mg on 1 day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide (administered by PDS290 pen)
Description: Subjects will receive 1 single dose of semaglutide 0.25 mg on 1 day
Study: NCT02122081

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo allogeneic peripheral blood progenitor cell or bone marrow transplant

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00284297

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: History taken and clinical examination
Description: History is taken and clinical examination is followed
Study: NCT01298856

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hydrotherapy
Description: hydrotherapy and ankle taping and land-based

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hydrotherapy
Description: hydrotherapy and ankle taping and land-based
Study: NCT04022499

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Presessions
Description: The Pre-NDPP arm includes a pre-session with three components: 1) education about diabetes risks, 2) motivational interviewing (MI) to encourage participation in the NDPP and, 3) problem-solving of barriers to engagement.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: National Diabetes Prevention Program
Description: The Diabetes Prevention Program was a successful clinical trial demonstrating that intensive lifestyle support for weight loss reduced diabetes incidence by 58%. The intervention was translated into the National Diabetes Prevention Program (NDPP) and disseminated by the Centers for Disease Control and Prevention as a yearlong group-based program since 2012.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: National Diabetes Prevention Program
Description: The Diabetes Prevention Program was a successful clinical trial demonstrating that intensive lifestyle support for weight loss reduced diabetes incidence by 58%. The intervention was translated into the National Diabetes Prevention Program (NDPP) and disseminated by the Centers for Disease Control and Prevention as a yearlong group-based program since 2012.
Study: NCT04143113

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision Aid
Description: Shared decision making tool
Study: NCT02380846

Intervention type: OTHER
Group type: OTHER
Intervention: White rice
Description: Control - white rice

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rice with chicken breast
Description: Treatment 1 - steamed white rice with steamed chicken breast

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rice with fish
Description: Treatment 2 - steamed white rice with steamed fish

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rice with egg white
Description: Treatment 3 - steamed white rice with egg white

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rice with beancurd
Description: Treatment 4 - steamed white rice with steamed beancurd
Study: NCT04060823

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Easy Breathing program
Description: Easy Breathing is a longstanding, nationally recognized program that translates asthma management guidelines into a standardized and usable format for healthcare providers. As part of the program primary healthcare providers will identify children at-risk for adverse asthma outcomes and provide care coordination services. Patients receive a tailored, comprehensive Asthma Treatment Plan with information regarding daily medication use and management of acute symptoms based on asthma severity.
Study: NCT03395821

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional training
Description: traditional training according to residency program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality+conventional training
Description: virtual reality training+traditional training using virtual reality
Study: NCT01974895

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FluLaval® Quadrivalent
Description: 1 or 2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm (for subjects ≥12 months of age) or anterolateral region of left thigh (for subjects \<12 months of age) on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects), respectively.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone®
Description: 1 or 2 doses administered IM in deltoid region of non-dominant arm (for subjects ≥12 months of age) or anterolateral region of left thigh (for subjects \<12 months of age) on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects), respectively.
Study: NCT00662129

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel albumin-stabilized nanoparticle formulation
Study: NCT04601584

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cohort 1, GNR-084
Description: 0.01 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cohort 2, GNR-084
Description: 0.1 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cohort 3, GNR-084
Description: 1 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles
Study: NCT03477994

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: an infusion of 0.5-0.7 μg/kg/h then 1.4 μg/kg/h if Richmond assessment sedation score from +1 to +4 ,if the heart rate less than 60 per minute or persistent hypotension reduce infusion rate by 0.2 μg/kg/h.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Clonidine
Description: an infusion of 0.5μg/kg then 0.1-0.2 μg/kg/h if Richmond assessment sedation score from +1 to +4.
Study: NCT04477044

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study Group
Description: GoPro Hero4 to be mounted on the participant's forehead while performing intubation on a manikin.
Study: NCT03768024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRT0151Y 50 mg capsule
Description: GRT0151Y 50 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRT0151Y 50 mg capsule
Description: GRT0151Y 50 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRT0151Y 50 mg capsule
Description: GRT0151Y 50 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone IR 4 mg
Description: Hydromorphone IR 4 mg tablet (encapsulated)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone IR 4 mg
Description: Hydromorphone IR 4 mg tablet (encapsulated)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone IR 4 mg
Description: Hydromorphone IR 4 mg tablet (encapsulated)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Matching placebo